TüCAD2 Lectures

A series of scientific talks in the framework of "Tübingen Center for Academic Drug Discovery & Development (TÜCAD2)-Lecture series".

Topic WS 2020/2021 Date (on Tuesdays) Presentation by

Cancer Immunotherapy, Part 1. Checkpoint Inhibitors.

November 24th, 2020 / 5 p.m. Dr. K. Ritter
Cancer Immunotherapy, Part 2. Small Molecule Approaches for Cancer Immunotherapy. December 8th, 2020 / 5 p.m. Dr. K. Ritter
Innovation Process and Productivity in Big pharma and Biotech. December 15th, 2020 / 6.30 p.m. Dr. Th. Rudolph
ADME-Aspects in Early Drug Discovery January 12th, 2020 / 5 p.m Dr. W.Albrecht
Cancer Immunotherapy, Part 3. Car T Cell Therapy and mRNA Vaccination  January 19th 2021 / 5 p.m. Dr. K. Ritter
Treatment of Multiple Sclerosis February 9th, 2021 / 5 p.m. Dr. K. Ritter

The lectures will be held as “Zoom“ meetings and are primarily designed for advanced (postgraduate, Master or Ph.D.) students, but everyone is cordially invited to attend!

For Zoom meeting IDs and passwords please contact the coordinator of this series, Dr. Thanigaimalai Pillaiyar (Mr.) (email)


Without restrictions regarding the specific medical area or indication, each scientific innovation with the potential of translation from basic research to clinical application is being supported. Currently, TüCAD2 supports projects in oncology, infectious diseases, regenerative medicine and cardiovascular diseases. High quality projects are highlighted and made visible to potential external collaborators.
In addition, TüCAD2 offers coaching and consultancy in terms of academic drug discovery, project setup, validation, development plans and project management through internal resources and external networks of experts.
Another key asset is TüKIC, the Tübingen Kinase Inhibitor Collection, a >8.000 compound proprietary library of fully characterized kinase inhibitors with more than 1 Mio. data sets.
The platform focuses various regional expertises. Thus there is a close collaboration between the University of Tübingen, the University Hospital of Tübingen, the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) Stuttgart and the Natural and Medical Sciences Institute (NMI) Reutlingen.

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology

Natural and Medical Sciences Institute